DaVita HealthCare Partners Inc. (NYSE:DVA) was upgraded by investment analysts at Wolfe Research from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, The Fly reports.

DVA has been the subject of a number of other reports. Royal Bank Of Canada reiterated a “hold” rating and set a $64.00 target price on shares of DaVita HealthCare Partners in a research report on Wednesday, September 6th. J P Morgan Chase & Co downgraded DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a research report on Monday, October 9th. BidaskClub downgraded DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. TheStreet downgraded DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research report on Wednesday, August 2nd. Finally, SunTrust Banks, Inc. set a $57.00 target price on DaVita HealthCare Partners and gave the company a “hold” rating in a research report on Sunday, October 15th. Four research analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company. DaVita HealthCare Partners has a consensus rating of “Hold” and an average price target of $65.00.

DaVita HealthCare Partners (NYSE DVA) traded up 3.27% on Monday, hitting $61.29. 2,049,758 shares of the company’s stock traded hands. DaVita HealthCare Partners has a 12 month low of $53.58 and a 12 month high of $70.16. The stock has a 50 day moving average price of $58.32 and a 200-day moving average price of $62.55. The stock has a market cap of $11.72 billion, a P/E ratio of 9.34 and a beta of 0.90.

DaVita HealthCare Partners (NYSE:DVA) last posted its earnings results on Tuesday, August 1st. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.02. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.82 billion. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.01 EPS. Equities analysts predict that DaVita HealthCare Partners will post $3.59 earnings per share for the current fiscal year.

DaVita HealthCare Partners announced that its Board of Directors has initiated a share repurchase program on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: “DaVita HealthCare Partners Inc. (DVA) Stock Rating Upgraded by Wolfe Research” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/23/davita-healthcare-partners-inc-dva-stock-rating-upgraded-by-wolfe-research.html.

A number of institutional investors and hedge funds have recently modified their holdings of DVA. PGGM Investments bought a new stake in DaVita HealthCare Partners in the second quarter worth $28,598,000. Oak Associates Ltd. OH lifted its position in DaVita HealthCare Partners by 225.3% in the first quarter. Oak Associates Ltd. OH now owns 152,910 shares of the company’s stock worth $10,393,000 after buying an additional 105,910 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in DaVita HealthCare Partners by 33.1% in the second quarter. Canada Pension Plan Investment Board now owns 387,370 shares of the company’s stock worth $25,086,000 after buying an additional 96,282 shares during the last quarter. Airain ltd bought a new stake in DaVita HealthCare Partners in the second quarter worth $2,234,000. Finally, Bank of Nova Scotia lifted its position in DaVita HealthCare Partners by 870.2% in the first quarter. Bank of Nova Scotia now owns 35,635 shares of the company’s stock worth $2,422,000 after buying an additional 31,962 shares during the last quarter. Institutional investors own 83.23% of the company’s stock.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

The Fly

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.